Showing results (2681-2690 of 45,231) with videos related to

Sort By:
Pageof 4,524
Cancer Research|October 21, 2010
K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasiaTomoyuki Okumura, Russell E Ericksen, Shigeo Takaishi, et al.
Cancer Research|October 21, 2010
Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinomaYun-Han Lee, Jesper B Andersen, Ho-Taek Song, et al.
Cancer Research|December 2, 2010
Novel metastasis-related gene CIM functions in the regulation of multiple cellular stress-response pathwaysKiyoshi Yanagisawa, Hiroyuki Konishi, Chinatsu Arima, et al.
Cancer Research|December 2, 2010
Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patientsChen Wu, Binghe Xu, Peng Yuan, et al.
Cancer Research|December 2, 2010
Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic modelMarianne O Stefanini, Florence T H Wu, Feilim Mac Gabhann, et al.
Cancer Research|April 1, 1990
Long term effects of benzo(a)pyrene on the activity of NAD(P)H:quinone reductase in the forestomach and glandular stomach of ICR/Ha miceA D Jassim, V L Sparins, L W Wattenberg
Cancer Research|July 1, 1990
Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillanceP L Ward, H K Koeppen, T Hurteau, et al.
Cancer Research|December 3, 2010
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistanceGerrit J P Dijkgraaf, Bruno Alicke, Lasse Weinmann, et al.
Cancer Research|December 3, 2010
A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGFNunzio Iraci, Daniel Diolaiti, Antonella Papa, et al.
Cancer Research|December 3, 2010
Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapyHoon Sim, Kristin Bibee, Samuel Wickline, et al.
Pageof 4,524